Broadwood Capital Inc Lineage Cell Therapeutics, Inc. Transaction History
Broadwood Capital Inc
- $1.2 Billion
- Q1 2025
A detailed history of Broadwood Capital Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Broadwood Capital Inc holds 49,560,992 shares of LCTX stock, worth $46.6 Million. This represents 1.86% of its overall portfolio holdings.
Number of Shares
49,560,992
Previous 41,666,255
18.95%
Holding current value
$46.6 Million
Previous $20.8 Million
7.05%
% of portfolio
1.86%
Previous 1.65%
Shares
4 transactions
Others Institutions Holding LCTX
# of Institutions
139Shares Held
108MCall Options Held
8KPut Options Held
3K-
Black Rock Inc. New York, NY9.56MShares$8.99 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$8.38 Million0.0% of portfolio
-
Defender Capital, Llc.6.31MShares$5.93 Million1.19% of portfolio
-
Raffles Associates LP New York, NY5.64MShares$5.3 Million3.45% of portfolio
-
Geode Capital Management, LLC Boston, MA4.49MShares$4.22 Million0.0% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $160M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...